Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cel...
Gespeichert in:
Veröffentlicht in: | Proceedings of the National Academy of Sciences - PNAS 2009-08, Vol.106 (31), p.12879-12884 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 12884 |
---|---|
container_issue | 31 |
container_start_page | 12879 |
container_title | Proceedings of the National Academy of Sciences - PNAS |
container_volume | 106 |
creator | Sola, Caroline André, Pascale Lemmers, Céline Fuseri, Nicolas Bonnafous, Cécile Bléry, Mathieu Wagtmann, Nicolai R Romagné, François Vivier, Eric Ugolini, Sophie |
description | Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I⁺ cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA⁺ target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients. |
doi_str_mv | 10.1073/pnas.0901653106 |
format | Article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmed_primary_19561305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40484619</jstor_id><sourcerecordid>40484619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c654t-ae8eaa354f362125bb405ff1831a3dec6ef1e80d15f940da441904a935cc94fa3</originalsourceid><addsrcrecordid>eNqFks1v1DAQxSMEokvhzAmIOCBxSDsTfyS-IFUVtEgrcYCeLW9ib71k7cV2VvS_xyGrLvTSg2XJ7zfPM6NXFK8RzhAacr5zKp6BAOSMIPAnxQJBYMWpgKfFAqBuqpbW9KR4EeMGAARr4XlxgoJxJMAWRXelnU62K5Xr80l25fu7aqt7q5Luy6B3wa-D2m6tW5felE6lMaih_GmHQYey08NQbm2MWa6iHkyu6Pza2WS9K60r93bvXxbPjBqifnW4T4ubL59_XF5Xy29XXy8vllXHGU2V0q1WijBqCK-xZqsVBWYMtgQV6XXHtUHdQo_MCAq9ohQFUCUI6zpBjSKnxafZdzeu8gSddim3KnfBblW4k15Z-b_i7K1c-72sm7omlGaDj7PB7YOy64ulnN4AKMGWN3vM7IfDZ8H_GnVMMq9hWody2o9R8oY1lAjxKFhDC01NJvD9A3Djx-DyxjKDFLFtpm_PZ6gLPsagzX2fCHKKhJwiIY-RyBVv_93KkT9k4Dj138qjHZcEJdZtI6QZhyHp3ymz5SNsRt7MyCYmH-4ZCrSlHCf93awb5aVaBxvlzfc8IMkdc0prQv4AYMneXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201411871</pqid></control><display><type>article</type><title>Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Sola, Caroline ; André, Pascale ; Lemmers, Céline ; Fuseri, Nicolas ; Bonnafous, Cécile ; Bléry, Mathieu ; Wagtmann, Nicolai R ; Romagné, François ; Vivier, Eric ; Ugolini, Sophie</creator><creatorcontrib>Sola, Caroline ; André, Pascale ; Lemmers, Céline ; Fuseri, Nicolas ; Bonnafous, Cécile ; Bléry, Mathieu ; Wagtmann, Nicolai R ; Romagné, François ; Vivier, Eric ; Ugolini, Sophie</creatorcontrib><description>Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I⁺ cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA⁺ target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.0901653106</identifier><identifier>PMID: 19561305</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Animals ; Antibodies ; Antibodies, Monoclonal ; Antibodies, Monoclonal - therapeutic use ; Biological Sciences ; Blood ; Cancer ; Cell Line ; Cells ; HLA antigens ; HLA-C Antigens ; HLA-C Antigens - physiology ; Humans ; Immunity, Innate ; Immunology ; Killer Cells, Natural ; Killer Cells, Natural - immunology ; Life Sciences ; Ligands ; Lymphocytes ; Mice ; Mice, Inbred C57BL ; Molecules ; Monoclonal antibodies ; Natural killer cells ; Neoplasms, Experimental ; Neoplasms, Experimental - immunology ; Neoplasms, Experimental - therapy ; Receptors ; Receptors, KIR2DL3 ; Receptors, KIR2DL3 - immunology ; Receptors, KIR2DL3 - physiology ; Rodents ; Self Tolerance ; Splenocytes ; T lymphocytes ; Tumors</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.12879-12884</ispartof><rights>Copyright National Academy of Sciences Aug 4, 2009</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c654t-ae8eaa354f362125bb405ff1831a3dec6ef1e80d15f940da441904a935cc94fa3</citedby><cites>FETCH-LOGICAL-c654t-ae8eaa354f362125bb405ff1831a3dec6ef1e80d15f940da441904a935cc94fa3</cites><orcidid>0000-0003-4041-0103 ; 0000-0001-7022-8287</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/106/31.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40484619$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40484619$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27901,27902,53766,53768,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19561305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00431867$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Sola, Caroline</creatorcontrib><creatorcontrib>André, Pascale</creatorcontrib><creatorcontrib>Lemmers, Céline</creatorcontrib><creatorcontrib>Fuseri, Nicolas</creatorcontrib><creatorcontrib>Bonnafous, Cécile</creatorcontrib><creatorcontrib>Bléry, Mathieu</creatorcontrib><creatorcontrib>Wagtmann, Nicolai R</creatorcontrib><creatorcontrib>Romagné, François</creatorcontrib><creatorcontrib>Vivier, Eric</creatorcontrib><creatorcontrib>Ugolini, Sophie</creatorcontrib><title>Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I⁺ cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA⁺ target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological Sciences</subject><subject>Blood</subject><subject>Cancer</subject><subject>Cell Line</subject><subject>Cells</subject><subject>HLA antigens</subject><subject>HLA-C Antigens</subject><subject>HLA-C Antigens - physiology</subject><subject>Humans</subject><subject>Immunity, Innate</subject><subject>Immunology</subject><subject>Killer Cells, Natural</subject><subject>Killer Cells, Natural - immunology</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Molecules</subject><subject>Monoclonal antibodies</subject><subject>Natural killer cells</subject><subject>Neoplasms, Experimental</subject><subject>Neoplasms, Experimental - immunology</subject><subject>Neoplasms, Experimental - therapy</subject><subject>Receptors</subject><subject>Receptors, KIR2DL3</subject><subject>Receptors, KIR2DL3 - immunology</subject><subject>Receptors, KIR2DL3 - physiology</subject><subject>Rodents</subject><subject>Self Tolerance</subject><subject>Splenocytes</subject><subject>T lymphocytes</subject><subject>Tumors</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1v1DAQxSMEokvhzAmIOCBxSDsTfyS-IFUVtEgrcYCeLW9ib71k7cV2VvS_xyGrLvTSg2XJ7zfPM6NXFK8RzhAacr5zKp6BAOSMIPAnxQJBYMWpgKfFAqBuqpbW9KR4EeMGAARr4XlxgoJxJMAWRXelnU62K5Xr80l25fu7aqt7q5Luy6B3wa-D2m6tW5felE6lMaih_GmHQYey08NQbm2MWa6iHkyu6Pza2WS9K60r93bvXxbPjBqifnW4T4ubL59_XF5Xy29XXy8vllXHGU2V0q1WijBqCK-xZqsVBWYMtgQV6XXHtUHdQo_MCAq9ohQFUCUI6zpBjSKnxafZdzeu8gSddim3KnfBblW4k15Z-b_i7K1c-72sm7omlGaDj7PB7YOy64ulnN4AKMGWN3vM7IfDZ8H_GnVMMq9hWody2o9R8oY1lAjxKFhDC01NJvD9A3Djx-DyxjKDFLFtpm_PZ6gLPsagzX2fCHKKhJwiIY-RyBVv_93KkT9k4Dj138qjHZcEJdZtI6QZhyHp3ymz5SNsRt7MyCYmH-4ZCrSlHCf93awb5aVaBxvlzfc8IMkdc0prQv4AYMneXA</recordid><startdate>20090804</startdate><enddate>20090804</enddate><creator>Sola, Caroline</creator><creator>André, Pascale</creator><creator>Lemmers, Céline</creator><creator>Fuseri, Nicolas</creator><creator>Bonnafous, Cécile</creator><creator>Bléry, Mathieu</creator><creator>Wagtmann, Nicolai R</creator><creator>Romagné, François</creator><creator>Vivier, Eric</creator><creator>Ugolini, Sophie</creator><general>National Academy of Sciences</general><general>National Acad Sciences</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4041-0103</orcidid><orcidid>https://orcid.org/0000-0001-7022-8287</orcidid></search><sort><creationdate>20090804</creationdate><title>Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo</title><author>Sola, Caroline ; André, Pascale ; Lemmers, Céline ; Fuseri, Nicolas ; Bonnafous, Cécile ; Bléry, Mathieu ; Wagtmann, Nicolai R ; Romagné, François ; Vivier, Eric ; Ugolini, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c654t-ae8eaa354f362125bb405ff1831a3dec6ef1e80d15f940da441904a935cc94fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological Sciences</topic><topic>Blood</topic><topic>Cancer</topic><topic>Cell Line</topic><topic>Cells</topic><topic>HLA antigens</topic><topic>HLA-C Antigens</topic><topic>HLA-C Antigens - physiology</topic><topic>Humans</topic><topic>Immunity, Innate</topic><topic>Immunology</topic><topic>Killer Cells, Natural</topic><topic>Killer Cells, Natural - immunology</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Molecules</topic><topic>Monoclonal antibodies</topic><topic>Natural killer cells</topic><topic>Neoplasms, Experimental</topic><topic>Neoplasms, Experimental - immunology</topic><topic>Neoplasms, Experimental - therapy</topic><topic>Receptors</topic><topic>Receptors, KIR2DL3</topic><topic>Receptors, KIR2DL3 - immunology</topic><topic>Receptors, KIR2DL3 - physiology</topic><topic>Rodents</topic><topic>Self Tolerance</topic><topic>Splenocytes</topic><topic>T lymphocytes</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sola, Caroline</creatorcontrib><creatorcontrib>André, Pascale</creatorcontrib><creatorcontrib>Lemmers, Céline</creatorcontrib><creatorcontrib>Fuseri, Nicolas</creatorcontrib><creatorcontrib>Bonnafous, Cécile</creatorcontrib><creatorcontrib>Bléry, Mathieu</creatorcontrib><creatorcontrib>Wagtmann, Nicolai R</creatorcontrib><creatorcontrib>Romagné, François</creatorcontrib><creatorcontrib>Vivier, Eric</creatorcontrib><creatorcontrib>Ugolini, Sophie</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sola, Caroline</au><au>André, Pascale</au><au>Lemmers, Céline</au><au>Fuseri, Nicolas</au><au>Bonnafous, Cécile</au><au>Bléry, Mathieu</au><au>Wagtmann, Nicolai R</au><au>Romagné, François</au><au>Vivier, Eric</au><au>Ugolini, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2009-08-04</date><risdate>2009</risdate><volume>106</volume><issue>31</issue><spage>12879</spage><epage>12884</epage><pages>12879-12884</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I⁺ cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA⁺ target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>19561305</pmid><doi>10.1073/pnas.0901653106</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4041-0103</orcidid><orcidid>https://orcid.org/0000-0001-7022-8287</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8424 |
ispartof | Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.12879-12884 |
issn | 0027-8424 1091-6490 |
language | eng |
recordid | cdi_pubmed_primary_19561305 |
source | Jstor Complete Legacy; MEDLINE; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
subjects | Animals Antibodies Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Biological Sciences Blood Cancer Cell Line Cells HLA antigens HLA-C Antigens HLA-C Antigens - physiology Humans Immunity, Innate Immunology Killer Cells, Natural Killer Cells, Natural - immunology Life Sciences Ligands Lymphocytes Mice Mice, Inbred C57BL Molecules Monoclonal antibodies Natural killer cells Neoplasms, Experimental Neoplasms, Experimental - immunology Neoplasms, Experimental - therapy Receptors Receptors, KIR2DL3 Receptors, KIR2DL3 - immunology Receptors, KIR2DL3 - physiology Rodents Self Tolerance Splenocytes T lymphocytes Tumors |
title | Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A25%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20and%20antibody-mediated%20reprogramming%20of%20natural%20killer%20cell%20missing-self%20recognition%20in%20vivo&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Sola,%20Caroline&rft.date=2009-08-04&rft.volume=106&rft.issue=31&rft.spage=12879&rft.epage=12884&rft.pages=12879-12884&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.0901653106&rft_dat=%3Cjstor_pubme%3E40484619%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201411871&rft_id=info:pmid/19561305&rft_jstor_id=40484619&rfr_iscdi=true |